Laurus Labs approves FY26 Audited Results, Q4 FY26 Results, and 2nd Interim Dividend of ₹1.20/share
Laurus Labs approved audited financial results for FY26 and Q4 FY26. The company declared a second interim dividend of ₹1.20 per share, with May 8, 2026, as the record date. The 21st AGM is scheduled for July 2, 2026, with a June 25, 2026, e-voting cut-off date.
The approval of financial results and dividend declaration are material events for investors. The upcoming AGM is a routine corporate event. The impact is considered medium as it confirms financial performance and provides a return to shareholders.
The announcement includes the approval of audited financial results and the declaration of an interim dividend, which are generally positive for shareholders. The unmodified audit opinion further strengthens the positive sentiment.
Laurus Labs Limited announced the outcome of its Board Meeting held on April 30, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the fiscal year ended March 31, 2026, and the Limited Reviewed Financial Results for the fourth quarter ended March 31, 2026. The Statutory Auditors, Deloitte Haskins & Sells LLP, have issued an 'Unmodified Opinion' on the audited financial statements for the year ended March 31, 2026.
In addition, the Board approved the payment of the second interim dividend for FY 2025-26 at a rate of ₹1.20 per equity share (60%) of ₹2 each. The record date for this dividend has been fixed as May 08, 2026, and the dividend will be paid on or after May 20, 2026.
Furthermore, the Board has approved the convening of the 21st Annual General Meeting (AGM) of the Company on Thursday, July 02, 2026, to be conducted through Video Conferencing / Other Audio Visual Means. The cut-off date for e-voting in connection with the 21st AGM has been set as June 25, 2026.
The Board Meeting commenced at 02:00 p.m. and concluded at 03:00 p.m. The financial results are available on the company's website and the websites of BSE Limited and the National Stock Exchange of India Ltd.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.